TCGA-55-A48Y-01A-11R-A24H-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.590
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- PANCREAS_BETA_CELLS+0.390
- COAGULATION+0.250
- KRAS_SIGNALING_UP+0.230
- CHOLESTEROL_HOMEOSTASIS+0.190
- XENOBIOTIC_METABOLISM+0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- ANDROGEN_RESPONSE+0.140
- MYOGENESIS+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.450
- DNA_REPAIR-0.400
- E2F_TARGETS-0.290
- MITOTIC_SPINDLE-0.260
- OXIDATIVE_PHOSPHORYLATION-0.260
- MYC_TARGETS_V2-0.220
- INTERFERON_GAMMA_RESPONSE-0.210
- P53_PATHWAY-0.210
- MYC_TARGETS_V1-0.190
- G2M_CHECKPOINT-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5930-01A-11R-1755-07 | — | cohortA4 | 0.776 |
| 2 | MNG313 | — | — | 0.757 |
| 3 | 773b41d4-8c43-4777-99b8-190c7e7793e0 | — | — | 0.748 |
| 4 | TCGA-DK-A2I1-01A-11R-A180-07 | — | — | 0.747 |
| 5 | TCGA-AR-A1AN-01A-11R-A12P-07 | — | A | 0.733 |
| 6 | TCGA-UF-A718-01A-22R-A34R-07 | — | — | 0.733 |
| 7 | TCGA-FD-A3SL-01A-21R-A22U-07 | — | — | 0.730 |
| 8 | SAMN03290943 | — | — | 0.729 |
| 9 | 3d97737f-01a1-43f1-ba35-ee7cc84dc7ff | — | — | 0.724 |
| 10 | MBCProject_0063_T3B_RNA | — | A | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.590 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |